The global Central Precocious Puberty Market is estimated to be valued at US$ 1.722.2 Mn in 2023 and is expected to exhibit a CAGR of 7.9% over the forecast period 2028 to 2030, as highlighted in a new report published by Coherent Market Insights.
Central precocious puberty (CPP) is an early start of sexual maturation before the typical age of puberty which is usually 8 years for girls and 9 years for boys. If left untreated, CPP can negatively impact physical and emotional development as well as adult height. Gonadotropin-releasing hormone (GnRH) analogs are primarily used to delay puberty and allow normal growth.
Market key trends:
Use of long acting gonadotropin-releasing hormone (GnRH) analogs: Long acting GnRH agonists such as leuprolide acetate injections and histrelin implants given every 3-6 months are replacing daily injections, offering better compliance and treatment outcomes. Their extended dosing reduces treatment burden and risk of early pubertal development between injections.
Market key trends:
The central precocious puberty market is witnessing growing adoption of GnRH agonists as the first line therapy. GnRH agonists help pause puberty by blocking the stimulation of the gonadal axis, allowing children to reach appropriate age before the start of puberty. Within GnRH agonists, leuprolide acetate is the most commonly prescribed drug owing to its long clinical history and safety profile. However, non-invasive alternative treatments are gaining interest to avoid complications from long-term GnRH agonists usage.
Strength: GnRH agonists are established as the standard first line therapy with leuprolide acetate having a well-established safety profile.
Weakness: Long term usage of GnRH agonists can cause adverse effects like loss of bone mineral density.
Opportunity: Rising awareness about CPP and its treatments present an opportunity for market players to expand presence.
Threats: Entry of generic competitors once patents of established brands expire can impact prices. Also, non-invasive alternative treatments pose a threat.
The global central precocious puberty market is expected to witness high growth, exhibiting CAGR of 7.9% over the forecast period 2028 to 2030, due to increasing number of diagnosed CPP cases and rising awareness.
Regionally, North America dominated the central precocious puberty market in 2023 and is expected to continue its dominance throughout the forecast period. This is attributed to growing healthcare expenditure and early diagnosis in the region.
Key players operating in the central precocious puberty market are Teva Pharmaceutical Industries Ltd., AbbVie Inc., Arbor Pharmaceuticals, LLC, Pfizer Inc., Tolmar Pharmaceuticals, Inc., Endo International plc, Ipsen Pharma, Debiopharm Group, and Sun Pharmaceutical Industries Limited. The market is dominated by major players offering established therapies like leuprolide acetate and histrelin.